BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study

Reuters12-03

Dec 3 (Reuters) - Pharvaris NV PHVS.O:

PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM RAPIDE-3 PIVOTAL STUDY CONFIRMING POTENTIAL OF DEUCRICTIBANT FOR ON-DEMAND TREATMENT OF HAE ATTACKS
PHARVARIS NV - PRIMARY ENDPOINT MET WITH SYMPTOM RELIEF IN 1.28 HOURS
PHARVARIS NV - ALL SECONDARY EFFICACY ENDPOINTS MET IN RAPIDE-3 STUDY
PHARVARIS NV - DEUCRICTIBANT CONFIRMED TO HAVE WELL-TOLERATED SAFETY PROFILE
PHARVARIS NV - TO SUBMIT NDA TO FDA IN FIRST HALF OF 2026

Source text: ID:nGNX36XB0D

Further company coverage: PHVS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588046198?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 20:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588046198","market":"us","top_or_hot":-1,"title":"BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study </title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span>Pharvaris NV <span>PHVS.O</span>:</p><ul><li><p>PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM RAPIDE-3 PIVOTAL STUDY CONFIRMING POTENTIAL OF DEUCRICTIBANT FOR ON-DEMAND TREATMENT OF HAE ATTACKS</p></li><li><p>PHARVARIS NV - PRIMARY ENDPOINT MET WITH SYMPTOM RELIEF IN 1.28 HOURS</p></li><li><p>PHARVARIS NV - ALL SECONDARY EFFICACY ENDPOINTS MET IN RAPIDE-3 STUDY</p></li><li><p>PHARVARIS NV - DEUCRICTIBANT CONFIRMED TO HAVE WELL-TOLERATED SAFETY PROFILE</p></li><li><p>PHARVARIS NV - TO SUBMIT NDA TO FDA IN FIRST HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNX36XB0D</span></p><p>Further company coverage: <span>PHVS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 20:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study </title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span>Pharvaris NV <span>PHVS.O</span>:</p><ul><li><p>PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM RAPIDE-3 PIVOTAL STUDY CONFIRMING POTENTIAL OF DEUCRICTIBANT FOR ON-DEMAND TREATMENT OF HAE ATTACKS</p></li><li><p>PHARVARIS NV - PRIMARY ENDPOINT MET WITH SYMPTOM RELIEF IN 1.28 HOURS</p></li><li><p>PHARVARIS NV - ALL SECONDARY EFFICACY ENDPOINTS MET IN RAPIDE-3 STUDY</p></li><li><p>PHARVARIS NV - DEUCRICTIBANT CONFIRMED TO HAVE WELL-TOLERATED SAFETY PROFILE</p></li><li><p>PHARVARIS NV - TO SUBMIT NDA TO FDA IN FIRST HALF OF 2026</p></li></ul><p>Source text: <span>ID:nGNX36XB0D</span></p><p>Further company coverage: <span>PHVS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHVS","symbol_name":"Pharvaris N.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUAHCGK8:1","article_id":"2588046198","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588046198","pubTimestamp":1764766633,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study Dec 3 (Reuters) - Pharvaris NV PHVS.O:PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM RAPIDE-3 PIVOTAL STUDY CONFIRMING POTEN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHVS":"Pharvaris N.V.","BK4007":"制药"},"translate_title":"简介-Pharvaris宣布Rapide-3关键研究的积极顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHVS":0.9},"content_text":"BRIEF-Pharvaris Announces Positive Topline Data From Rapide-3 Pivotal Study Dec 3 (Reuters) - Pharvaris NV PHVS.O:PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM RAPIDE-3 PIVOTAL STUDY CONFIRMING POTENTIAL OF DEUCRICTIBANT FOR ON-DEMAND TREATMENT OF HAE ATTACKSPHARVARIS NV - PRIMARY ENDPOINT MET WITH SYMPTOM RELIEF IN 1.28 HOURSPHARVARIS NV - ALL SECONDARY EFFICACY ENDPOINTS MET IN RAPIDE-3 STUDYPHARVARIS NV - DEUCRICTIBANT CONFIRMED TO HAVE WELL-TOLERATED SAFETY PROFILEPHARVARIS NV - TO SUBMIT NDA TO FDA IN FIRST HALF OF 2026Source text: ID:nGNX36XB0DFurther company coverage: PHVS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588046198","isCrawlerRequest":true}